newsfilter
← Latest News
GlobeNewswire·

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and